IQVIA Holdings (BSP:I1QV34) 3-Year EPS without NRI Growth Rate

: 81.70% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

IQVIA Holdings's EPS without NRI for the three months ended in Dec. 2023 was R$3.48.

During the past 12 months, IQVIA Holdings's average EPS without NRI Growth Rate was 74.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 81.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 54.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of IQVIA Holdings was 81.70% per year. The lowest was -34.60% per year. And the median was 12.60% per year.

Competitive Comparison

For the Diagnostics & Research subindustry, IQVIA Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IQVIA Holdings 3-Year EPS without NRI Growth Rate Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's 3-Year EPS without NRI Growth Rate falls into.

IQVIA Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

IQVIA Holdings (BSP:I1QV34) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

IQVIA Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IQVIA Holdings (BSP:I1QV34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (BSP:I1QV34) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

IQV:USA IQV:Mexico QTS:Germany QTS:Germany

Address

2400 Ellis Road, Durham, NC, USA, 27703

Website

https://www.iqvia.com

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Holdings (BSP:I1QV34) Headlines

No Headlines